The Orange T

AI, Robotics, and the Future of Drug Development

In Episode 7 of The Orange T, host Stephen M. Perry sits down with life sciences leader Nicholas Mandala to explore the forces reshaping drug development, pharmaceutical manufacturing, and healthcare innovation. From artificial intelligence in early drug discovery to robotics in aseptic manufacturing, the conversation explores how emerging technologies are accelerating scientific progress across the life sciences industry. Nick explains why AI - at the intersection of product and regulated spaces - is transforming molecular discovery, while still requiring a “human in the loop” to ensure quality, safety, and regulatory confidence. The discussion also examines how other industries like semiconductors may be decades ahead in automation, and what pharma can learn as billions of dollars flow into new manufacturing infrastructure. A broad sweeping discussion and dive into major industry shifts including: * The post-pandemic rebound in innovation * The upcoming pharmaceutical patent cliff * The rise of combination products and advanced drug delivery system * The growing role of digital health and connected therapies For scientists, engineers, and life sciences leaders, this episode offers a thoughtful look at how technology, leadership, and innovation are converging to shape the next era of healthcare. 🎧 Subscribe to The Orange T for conversations on leadership, innovation, and the future of life sciences. Recorded at Kymanox HQ in Research Triangle Park, North Carolina.

Make Your Own Blueprint: Dr. Sarah Glova on Labels, Fear, and Innovation

Stop looking for the perfect formula. Start building your own blueprint. Dr. Sarah Glova has a favorite slogan: "You can't compete with me because I want you to win too." This is the work she enjoys and has built a career on as an entrepreneur, educator, and researcher. And it's grounded in something most leadership advice isn't: actual science. In this episode, Sarah shares what her research reveals about innovation (hint: it's not about genius founders), how to manage fear without letting it drive, and why women business owners still face systemic barriers that most people don't see. She talks openly about being a mom at board meetings, saying no to opportunities that sound great but drain your calendar, and why showing up messy might be the most powerful thing a leader can do. Topics Include: * Owning the labels that matter (and letting go of the ones that don't) * What psychological safety actually means for innovative teams * The Benjamin Franklin effect: why asking for help strengthens relationships * Evidence-based confidence building (not the "fake it 'til you make it" kind) * Sarah's calendar hack for protecting your time and sanity * How to make face-to-face moments count in a hybrid world If you're leading a team, running a company, or trying to do ambitious work without losing yourself, this conversation offers a blueprint worth following—one grounded in research, honesty, and the belief that we all rise together. 🎧 Subscribe to The Orange T wherever you get your podcasts and follow Kymanox on LinkedIn [https://www.linkedin.com/company/kymanox/posts/?feedView=all]for more.

Building Partnerships, Not Pitches

Money fuels industry - and for many founders, finding investors is harder than building the technology itself. The average pre-seed founder takes 40–50 meetings before hearing a “yes.” Fifty times explaining your vision. Fifty times refining your pitch. Fifty times wondering if the right partner is out there. In this episode of The Orange T, Caleb Thornton, CEO of Seed2Table, believes the answer is simple — but not easy. Relationships. Not transactions. Not speed dating. Not spray-and-pray pitches. From cocktails designed as icebreakers to curated rooms where quality matters more than headcount, Caleb explains how Seed2Table helps founders and investors cut through the noise and build relationships. Topics include: * Why intentional relationship-building beats transactional networking * The psychology of surviving 50 investor meetings before a “yes” * How to avoid overselling your “moat” and stay focused on what matters * The importance of quality over quantity when curating events and connections Raising capital is about building partnerships, surrounding yourself with the right people, and learning to explain your value.  For founders and investors alike, this episode is a roadmap to being more intentional—and more successful—at the table. 🎧 Subscribe to The Orange T wherever you get your podcasts and follow Kymanox on LinkedIn for more.

Global Leadership Without Borders

In this episode of The Orange T, host Stephen M. Perry, Founder & CEO of Kymanox, sits down with global biopharma executive Roger Lias, PhD, for a candid look at what it takes to lead across borders, cultures, and time zones in today’s life science industry. From hierarchical boardrooms in India to fast-paced biotech in California, Roger shares stories and insights from a career that’s spanned the UK, US, Europe, and Asia. They explore how trust is built (and lost), why Americans sometimes miss nuance, and how embracing local customs can shape real business outcomes.  This episode supports those scientist turned leaders, early-career professionals, or a founder navigating growth, navigate global complexity to help you build respect, communicate effectively, and lead with empathy. Listen in and grow your T-shape team from every corner of the world. 🎧 Subscribe to Orange T wherever you get your podcasts and follow Kymanox on LinkedIn for more. #LifeSciences

The Heuro Health Approach to Better Type 2 Diabetes and Obesity Care

Obesity now affects 2 in 5 adults and 1 in 5 children in the U.S.—and it’s fueling an epidemic of chronic disease, from type 2 diabetes to cardiovascular issues to certain cancers. But traditional healthcare is still treating symptoms, not causes. In this episode of The Orange T, host Stephen M. Perry sits down with Jeff Bernhard (President) and Dr. Tom Walsh (Clinical Director) of Heuro Health to explore a different path forward. Heuro has built a 24-month, virtual-first care model designed to treat obesity holistically—combining clinical expertise, behavioral and lifestyle change, and data-driven outcomes. From GLP-1s to resistance training to employer partnerships, this conversation covers what truly works in chronic disease reversal of type 2 diabetes. 🔹 What GLP-1 medications are (and aren’t)  🔹 Why accessibility and accountability matter  🔹 How Heuro is helping self-funded employers reduce risk and cost  🔹 The emotional journey of patients reclaiming their health This episode is essential listening for anyone invested in public health, health equity, or fixing what’s broken in chronic care delivery.